Viewing data from:

GLYBURIDE (MICRONIZED)

ANDA

GLYBURIDE | A074686 | TEVA PHARMACEUTICALS USA INC

4 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$0.2394

per ea

Lowest NADAC/Unit

$0.1281

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00093803601GLYBURIDE MICRO 6 MG TABLET	$0.2394	EA	Generic	—	2026-04-22
00093803501GLYBURIDE MICRO 3 MG TABLET	$0.1281	EA	Generic	—	2026-04-22
00093803505GLYBURIDE MICRO 3 MG TABLET	$0.1281	EA	Generic	—	2026-04-22

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain7 active DMFs9 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

CAMBREX PROFARMACO MILANO SRLGLYBURIDE

DMF 76751988

USV PRIVATE LTDGLYBURIDE USP

DMF 158212002

CADILA PHARMACEUTICALS LTDGLYBURIDE USP

DMF 170932004

APITORIA PHARMA PRIVATE LTDGLYBURIDE USP

DMF 171522004

ZENTIVA KSGLYBURIDE USP (GLIBENCLAMIDE), MILLED

DMF 180182005

SRI KRISHNA PHARMACEUTICALS LTDGLYBURIDE USP

DMF 270452013

TIANJIN PHARMACEUTICAL HOLDINGS GENCOM PHARMACY CO LTDGLYBURIDE

DMF 299212015

FARMOS GROUP LTD MEDIPOLARInactiveGLYBURIDE

DMF 76381988

CADILA LABORATORIES PVT LTDInactiveGLYBURIDE BP'88 (GLIBENCLAMIDE)

DMF 79891989

SELOC FRANCEInactiveGLYBURIDE

DMF 110551994

HOECHST CELANESE CORPInactiveGLYBURIDE

DMF 111791994

AVENTIS PHARMA DEUTSCHLAND GMBHInactiveGLYBURIDE [MILLED (GROUND)]

DMF 121361996

AVENTIS PHARMA DEUTSCHLAND GMBHInactiveGLYBURIDE (MICRONIZED) BULK DRUG SUBSTANCE

DMF 121651996

USV LTDInactiveGLYBURIDE

DMF 143391999

CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDInactiveGLYBURIDE USP

DMF 182662005

CADILA HEALTHCARE LTDInactiveGLYBURIDE

DMF 192362006

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Apr 20, 1999	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — 1.5MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Apr 20, 1999

No patent or exclusivity listings for this strength.

#002 — 3MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Apr 20, 1999

#003 — 4.5MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Apr 20, 1999

#004 — 6MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Apr 20, 1999